Association between TERT gene polymorphisms and acute myeloid leukemia susceptibility in a Chinese population: a case-control study

Cancer Cell International
Yong TongZhiqiang Sun

Abstract

The aim of this study was to investigate the association between telomerase reverse transcriptase (TERT) gene polymorphisms and acute myeloid leukemia (AML) susceptibility in a Chinese Han population. A total of 102 AML patients and 108 healthy controls were enrolled in this case-control study. TERT gene rs2853669 and rs2736100 polymorphisms were genotyped via polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Chi-square test was applied to compare polymorphism distributions between case and control groups. The strength of the association between TERT gene polymorphisms and AML susceptibility was evaluated utilizing odds ratio (OR) with corresponding 95% confidence interval (CI). CC genotype and C allele of rs2736100 polymorphism were more frequent in AML patients (P < 0.05), and individuals carrying CC genotype showed higher risk of suffering from AML (OR = 2.632, 95% CI 1.129-6.133). But for rs2853669 polymorphism, no significant differences were detected in either genotype or allele distributions between groups (P > 0.05). This study suggested a positive association between TERT gene rs2736100 polymorphism and AML susceptibility in Chinese Han population.

References

Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Sep 13, 2007·British Journal of Cancer·S A SavageM Garcia-Closas
Jul 8, 2010·JAMA : the Journal of the American Medical Association·Peter WilleitStefan Kiechl
Mar 23, 2011·Seminars in Oncology·Lucy A GodleyMichelle M Le Beau
Apr 24, 2012·Journal of the National Cancer Institute·Simone MocellinDonato Nitti
Jan 26, 2013·Science·Franklin W HuangLevi A Garraway
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer
Sep 14, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellUNKNOWN National Comprehensive Cancer Network
Mar 13, 2014·Current Hematologic Malignancy Reports·Mohamad K Khasawneh, Omar Abdel-Wahab
Oct 9, 2014·Oncotarget·Lyubov ZaitsevaStuart A Rushworth
Jul 4, 2015·Human Molecular Genetics·Chenan ZhangUNKNOWN GECCO and GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and TRICL
Jul 8, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rongrong WeiWanqing Liu
Aug 25, 2015·Oncotarget·Mohamed Ali MosratiPeter Söderkvist
Aug 27, 2015·World Journal of Gastroenterology : WJG·Byung Joon ChoiWon Sang Park
Apr 1, 2016·Cancer Discovery·Jerry W Shay
Sep 22, 2017·JCI Insight·Simon KavanaghAaron D Schimmer

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
electrophoresis
PCR

Software Mentioned

Primer Premier
PASW statistics

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.